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Abstract
Goals—To define the clinical, biochemical and histologic features of liver injury from 
thiopurines.
Background—Azathioprine (Aza) and 6-mercaptopurine (6-MP) can cause liver injury but no 
large series exist.
Methods—Clinical and laboratory data and 6-months outcomes were analyzed from patients 
with thiopurine hepatotoxicity from the Drug-Induced Liver Injury Network Prospective Study.
Results—22 patients were identified, 12 due to Aza and 10 6-MP, with a median age of 55 years 
and the majority females (68%). Inflammatory bowel disease was the indication in 55%, and 
median thiopurine dose 150 (range 25–300) mg daily. The median latency to onset was 75 (range 3 
to 2584) days. Injury first arose after a dose escalation in 59% of patients; the median latency after 
dose increase being 44 (range 3 to 254) days. At onset, the median alanine aminotransferase was 
210 U/L, alkaline phosphatase 151 U/L and bilirubin 7.4 mg/dL (peak 13.4 mg/dL). There were no 
major differences between Aza and 6-MP cases, but anicteric cases typically had non-specific 
symptoms and a hepatocellular pattern of enzyme elevations, whereas icteric cases experienced a 
cholestatic hepatitis with modest enzyme elevations in a mixed pattern. One patient with pre-
existing cirrhosis required liver transplantation, all others resolved clinically. One patient still had 
moderate alkaline phosphatase elevations 2 years after onset.
Conclusions—Nearly three-quarters of patients with thiopurine-induced liver injury present 
with self-limited, cholestatic hepatitis, typically within 3 months of starting or a dose increase. The 
prognosis is favorable except in patients with pre-existing cirrhosis.
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Azathioprine (Aza) and 6-mercaptopurine (6-MP) are purine nucleoside analogues 
(thiopurines) that have potent antiproliferative and immunosuppressive activities and have 
been in common use for decades. 6-MP was introduced in the 1950s as an antineoplastic 
agent for the therapy of leukemias and lymphomas. Azathioprine, a prodrug of 6-MP, was 
introduced in the 1960s, but largely as an immunosuppressive agent, initially for prevention 
of transplant rejection and later for its corticosteroid sparing features as therapy of 
autoimmune diseases such as inflammatory bowel disease (IBD) and autoimmune hepatitis. 
Reports on liver injury, sometimes with a fatal outcome, associated with the use of these 
drugs appeared shortly after their introduction (1–7). Since then more than 100 cases of liver 
injury attributed to Aza and 6-MP have been reported (8). In many cases, the association was 
confirmed by a prompt recurrence of injury upon readminstration of the agent (9–14). In 
large, prospective (15–16) and retrospective studies on drug-induced liver injury, Aza and 6-
MP are frequently listed as common causes (17). Indeed, in a recent population-based study 
from Iceland, Aza was associated with the highest risk of hepatotoxicity, occurring in 1 of 
133 persons in whom it was prescribed (18).
Despite the common problem of hepatotoxicity with thiopurines there is a lack of studies 
with a significant number of well characterized patients with this type of liver injury. Most 
studies have been limited to the IBD patient population and focused largely on 
asymptomatic elevations of serum aminotransferase levels as the only evidence of liver 
injury (19–22). Clearly, both Aza and 6-MP are associated with transient elevations in serum 
enzyme levels, but these are usually mild, asymptomatic and self-limited and may resolve 
even without dose adjustment or temporary discontinuation (19). More importantly, both 
Aza and 6-MP have been implicated in instances of clinically apparent hepatotoxicity which 
can be severe leading to prolonged intrahepatic cholestasis (3, 7) or even to acute liver 
failure (2, 4, 5). Furthermore, both veno-occlusive disease (23) and nodular regenerative 
hyperplasia (24–25) have been well documented with higher doses and long-term treatment 
with these agents. Despite the number of case reports and case series, the severity and the 
overall clinical outcomes in patients with liver injury due to Aza and 6-MP have not been 
well defined. Furthermore, the cross-sensitivity to hepatotoxicity between Aza and 6-MP 
and possibly to the third thiopurine – 6-thioguanine (6-TG), has not been fully characterized.
The U.S. Drug-induced Liver Injury Network (DILIN) is a multicenter prospective cohort 
study which was started in 2004 with the primary aim to enroll patients with liver injury 
from drugs and dietary supplements to allow for better characterization of the clinical 
features, pathogenesis and outcomes of this poorly understood form of liver disease. The 
current analysis has focused on more fully characterizing the clinical, serologic and 
histological characteristics of the patients with liver injury attributed to the thiopurines who 
were enrolled in the DILIN study.
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METHODS
The study design of the prospective DILIN study has been described in detail in previous 
publications (16, 26). In brief, patients meeting pretermined eligibility criteria were enrolled 
for structured assessment of potential competing etiologies and thorough analysis of clinical 
features and laboratory testing results. Patients were followed for at least 6 months and, if 
clinical or laboratory features were still abnormal, were seen again at 12 and 24 months. The 
causality asessment and the overall diagnosis of drug-induced liver injury were based on 
adjudication by the DILIN Causality Committee using expert consensus (27). The strength 
of the relationship between the liver injury and the implicated agent was scored as definite 
(greater than 95% likelihood), very likely (75–94% likelihood), probable (50–74% 
likelihood), possible (25–49% likelihood) or unlikely (<25% likelihood) (20). In addition, 
the enrolling physician also applied the Rousell-Uclaf Causality Assessment Method 
(RUCAM) to the clinical information which generates a score from −9 to 14 and is classified 
as highly probable (9–14), probable (6–8), possible (3–5), unlikely (1–2) or excluded (≤ 0) 
(28). Finally, a severity score was assigned as (1) mild, with serum enzyme elevations 
without jaundice (bilirubin <2.5 mg/dL) or coagulopathy (INR <1.5), (2) moderate, with 
bilirubin ≥2.5 mg/dL or INR ≥ 1.5, (3) moderate, with bilirubin or INR elevations as above 
and hospitalized for liver injury, (4) severe, with jaundice and signs of liver failure (such as 
INR ≥ 1.5, ascites or hepatic encephalopathy) and (5) fatal, with liver-related death and/or 
liver transplantation within 6 months of onset of liver injury.
For the current analysis, all patients enrolled between September 2004 and September 2014 
with liver injury suspected to be due to thioprines were analyzed (Figure 1). Only those 
cases in which the causality was adjudicated as probable, very likely or definite were 
included. The clinical features, laboratory results and outcomes were obtained from the 
Duke Clinical Research Institute, the data coordinating center of the DILIN study. All 
patients were analysed by two of the authors (ESB, JHH) for clinical and laboratory features 
and outcomes such as progression to chronicity and liver-related death and need for liver 
transplantation. The type of liver injury was categorized on the basis of the R ratio 
calculated using the initial values of serum alanine aminotransferase (ALT) divided by 
alkaline phosphatase (Alk P), both expressed as ratios to upper limits of normal (ULN): R = 
ALT/ULN ÷ Alk P/ULN. By convention, R ratios less than 2 were defined as cholestatic, 2 
to 5 as mixed, and greater than 5 as hepatocellular (28). The type of liver injury was also 
assessed using the initial ALT and Alk P values graphed against each other using criteria 
established by Zimmerman (29).
Statistical analysis
Descriptive statistics of demographic and clinical data of Aza cases in comparison to 6-MP 
cases were generated and analyzed. Description of the data was given as medians (range), 
frequencies and percentages. Statistical significance among groups was determined by 
Wilcoxon rank-sum test for continuous variables, Fisher’s exact test for binary variables, 
Chi-square for categorical variables, and log-rank tests for time-to-event variables. P values 
of <0.05 were considered statistically significant. SAS v.9.4 [SAS Institute, Cary, NC] was 
used for all statistical analyses.
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Results
Clinical characteristics
Over the initial ten-year period of the prospective DILIN cohort study, 1434 cases of drug-
induced liver injury were enrolled and underwent causality assessment, of which 27 were 
attributed, at least in part, to a thioprine, including 15 to Aza, 12 to 6-MP but none to 6-TG 
(Figure 1). For this analysis, 5 cases were excluded in which liver injury was considered 
only possibly related to the thiopurine. The remaining 22 cases (12 attributed to Aza and 10 
to 6-MP) fulfilled the predefined criteria for inclusion and were used for the current analysis.
The demographics and initial clinical features of the 12 Aza and 10 6-MP cases are 
compared in Table 1. In most regards, the clinical features of cases associated with either 
drug were similar. The 22 cases included 15 women and 7 men, ages 11 to 66 years (mean 
51 years) and all except one (a 11 year boy receiving 6-MP for acute lymphocytic leukemia) 
were adults with an autoimmune condition. Most patient were white (n=20 including one 
Hispanic white) and two were African Americans. The most common indication for therapy 
was inflammatory bowel disease (IBD) (55%), followed by pulmonary disease of 
immunological nature (14%) (sarcoidosis, interstitial lung disease and idiopathic pulmonary 
fibrosis), autoimmune hepatitis (9%), systemic lupus erythematosus (9%) and 
dermatomyositis (9%).
The expert DILIN causality assessment was definite for 2 (9%), very likely for 12 (54%), 
and probable for 8 (36%) cases, and the distribution was similar for Aza and 6-MP. RUCAM 
scores were also similar with the two agents, the median being 6.5 overall with 4 cases rated 
highly probable (9–10), 14 probable (6–8) and 4 possible (4–5). Viral serologies were 
negative for hepatitis A, B, C and E in all patients except for one patient with known but 
stable pre-existing chronic hepatitis C. All patients underwent imaging of the liver and 
biliary tree (ultrasound in 73%, computerized tomography in 59% and magnetic resonance 
imaging in 27%) and none had evidence of biliary obstruction. Antinuclear antibodies were 
present in 5 patients (22%) but were thought to be due to the underlying condition (lupus, 
autoimmune hepatitis in 2, IBD in 2) in each case. Overall 10 patients (46%) were receiving 
corticosteroids when they developed liver injury. Only one patient was started on treatment 
with corticosteroids for the liver injury, but did not require long-term therapy.
All except one patient had symptoms attributable to the liver injury, the most common being 
jaundice (73%), nausea (64%), fatigue (50%) and abdominal pain (50%). Itching was 
reported in 6 patients (27%) but was generally transient and mild-to-moderate in severity. 
Rash (23%) and fever (27%) were reported in a minority of patients and were not prominent 
or severe. No patient was diagnosed as having DRESS syndrome or a severe cutaneous 
reaction.
The latency to onset, measured as time from starting the medication to identification of 
laboratory abnormalities, ranged widely from 3 days to almost 10 years, with median of 75 
days. Strikingly, 13 patients (59%) had an escalation of dose before the onset of liver injury 
and the median latency from the last dose increase (or initial dose if there were no increase) 
to onset was 44 days (range 3 to 254 days). The latency as measured from starting therapy 
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and from the time of the last dose increase is plotted in Figure 2 separately for each case of 
Aza and 6-MP induced liver injury. Overall 59% of cases developed laboratory evidence of 
DILI within 3 months of starting therapy and 86% within 3 months of the last dose increase. 
Using either measure, latencies were shorter for Aza than 6-MP cases, but the differences 
were of marginal statistical significance. The initial thiopurine dose ranged from 25 to 200 
mg (median = 75 mg) daily; the final dose from 50 to 450 mg (median = 150 mg) daily. The 
median initial and final daily doses were similar in those taking Aza or 6-MP expressed 
either as total daily dose or as mg/kg/day (Table 1).
Laboratory results are given in Table 2, comparing Aza and 6-MP related cases. Serum 
aminotransferase levels were elevated in all 22 patients, Alk P in 18 and bilirubin (≥ 2.5 
mg/dL) in 16. The initial median (and range) values for ALT were 211 (64–625) U/L, AST 
153 (47–603) U/L, Alk P 151 (35–412) U/L and bilirubin 7.4 (0.6–31.8) mg/dL. The median 
peak values were 13.8 mg/dL for bilirubin and 1.3 for INR. The R ratio at onset of injury 
ranged from cholestatic to hepatocellular and the most frequent pattern was in the “mixed 
hepatitis” range (2–5). These R ratios, however, failed to reflect the somewhat unusual 
relative ratios of ALT to Alk P. In most cases with jaundice, Alk P levels were only modestly 
elevated and some were withi the normal range, at least at the onset of illness. Concurrent 
ALT levels were generally in the moderate range and never greater than 10 fold elevated. 
When ALT and Alk P were plotted by absolute value in quadrants using the criteria 
established by Zimmerman (29), the values for jaundiced cases were in the range of 
“canalicular cholestasis” rather than hepatocellular, mixed or cholestatic hepatitis (Figure 3). 
This pattern is defined by ALT elevations less than 8 times ULN and Alk P levels less than 3 
times ULN and is most typical of the bland cholestasis that occurs with estrogen or anabolic 
steroid induced jaundice. Interestingly, among the 6 anicteric cases, the plotted values of 
ALT and Alk P were usually in the hepatocellular range and the median R ratio was 8.6 
(range 3–22), which was distinctly different from the more cholestatic pattern of the patients 
who developed jaundice (median R ratio = 2.5, range 1.1–14.2).
The severity of the acute liver injury was scored as mild in 6, moderate in 9 and severe in 7 
patients (Table 2). 6-MP associated cases tended to be more severe than the Aza cases both 
in terms of severity scores (5 of the 7 severe cases were due to 6-MP) as well as initial and 
peak bilirubin and INR values, but there was considerable overlap. No patient died, but one 
underwent liver transplantation: a 63 year old man with autoimmune hepatitis and cirrhosis 
who developed persistent jaundice 2 months after having 6-MP (150 mg daily) added to his 
corticosteroid therapy, with worsening coagulopathy and hepatic encephalopathy, leading to 
liver transplantation 41 days later. The histology of the explant revealed post necrotic 
cirrhosis, severe cholestasis and massive necrosis.
All other patients recovered from the acute liver injury clinically and all except 2 had normal 
liver tests at a final follow-up assessment. The first of the 2 had pre-existing chronic 
hepatitis C, and aminotransferase levels had been elevated before Aza was started. A second 
patient had persistent elevations in Alk P that had followed a severe cholestatic hepatitis and 
a liver biopsy that had shown duct injury and nodular regeneration attributed to 6-MP. At last 
follow up, no patient was jaundiced or had symptoms attributable to liver disease. No patient 
was rechallenged with Aza or 6-MP, but two gave a history of a previous episode of liver 
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injury due to Aza; one with a recurrence after re-exposure to Aza and one with recurrence 
upon treatment with 6-MP.
Liver biopsies were done during the acute episode on 8 patients, and 7 were available for 
central review, all among the jaundiced cases. The most common finding was cholestatic 
hepatitis with lobular and portal inflammation, zone 3 cholestasis and duct injury without 
duct loss (Figure 4a and 4b). No patient had findings typical of bland cholestasis. One 
patient had what appeared to be an underlying steatohepatitis and another had a severe 
autoimmune hepatitis with a superimposed cholestasis. Interestingly, reticulum staining 
showed that 3 patients had areas of nodular regeneration (Figure 4c). These 3 all had severe 
injury (peak bilirubin >20 mg/dL in all three) and had been treated for an extended period 
(73 to 460 days). One had persistent Alk P elevations even after 2 years of follow up and the 
other 2 resolved the injury both clinically and biochemically.
Thiopurine methyl transferase (TPMT) genotype analysis was available in only 4 patients 
and was normal in all. Thiopurine (6-MMP) metabolites were measured at the time of liver 
injury in two Aza-treated patients and were elevated in both, with values of 16,980 and 
21,856 pmol per 108 red blood cells. Stored serum samples were available from many 
patients, but not from the time of initial onset.
Concise clinical histories of 6 representative patients are provided in the Supplementary 
material: 2 had self-limited cholestatic hepatitis, 2 cholestatic hepatitis superimposed upon 
chronic liver disease and 2 anicteric hepatitis with hepatocellular enzyme elevations. The 
clinical courses of other cases are available on the LiverTox website (8).
Discussion
Aza and 6-MP are thiopurines with similar chemical structures and mechanisms of action. 
Aza acts as a prodrug of 6-MP, differing only by addition of an imido-azo side chain on the 
6′ sulfate. The side chain is removed non-enzymatically in the liver, and Aza tends to be 
better absorbed and perhaps better tolerated than 6-MP. Nevertheless, the two thiopurines 
have similar activities and side effects.
Both 6-MP and Aza are well known causes of drug-induced liver injury. At least 4 patterns 
of injury have been associated with their use. First, and most common, is transient and 
usually asymptomatic elevations in serum enzymes, mostly ALT and AST, that occurs in 5–
15% of treated subjects. In this series, 6 patients had this pattern of serum aminotransferase 
elevations accompanied by minor symptoms but without jaundice. More clinically 
significant is a second form of hepatotoxicity, an idiosyncratic, cholestatic hepatitis that 
typically occurs after 1 to 3 months of treatment. Indeed, the majority of cases in the current 
report, had this pattern; 16 patients presenting with jaundice and most with a cholestatic 
pattern. Both Aza and 6-MP are also capable of causing sinusoidal obstruction syndrome, a 
third form of hepatotoxicity that occurs when the agents are given in high doses as with 
cancer chemotherapy. Finally, both agents have also been linked to cases of nodular 
regenerative hyperplasia when given long-term, particularly in the setting of organ 
transplantation or acute leukemia. In this series, 3 of 7 patients who underwent liver biopsy 
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had histologic features of nodular regeneration, however, none subsequently progressed to 
developed signs or symptoms of portal hypertension. These four patterns of injury have also 
been described with thioguanine (23–25,30).
The current analysis showed that Aza and 6-MP associated liver injury accounted for 1–2% 
of cases of drug-induced liver injury in the DILIN network. Individually, Aza and 6-MP 
ranked in the top 20 causes of liver injury in the DILIN prospective study and if grouped 
together would have ranked as the 6th most common cause (16). In jaundiced cases, the 
disease was marked by appearance of fatigue, nausea, vomiting and abdominal discomfort 
followed by dark urine and jaundice. Itching was not common and immunoallergic features 
were rare, and if present generally mild. Strikingly, the latency to onset varied widely and 
some patients had been receiving the thiopurine for years when jaundice arose. In these 
patients, however, there was usually a history of recent increase in dose. Thus, the latency to 
onset after starting therapy or after a dose increase was generally a few weeks to 3 months, 
and rarely exceeded 6 months. While the course of illness could be severe, it was generally 
short lived and rapidly improved upon stopping treatment. Only one of the 22 patients had 
evidence of chronic liver injury in long-term follow up, marked by asymptomatic but 
persistent elevations in Alk P after a particularly severe bout of cholestatic hepatitis. No 
patient died with acute liver failure, although one patient with a pre-existing autoimmune 
hepatitis and cirrhosis developed an “acute-on-chronic” liver failure and required liver 
transplantation. Thus, in the absence of pre-existing liver disease, the hepatotoxicity of Aza 
and 6-MP tended to be benign.
In the current study an intriguing finding was the frequent occurrence of appearance of liver 
injury after dose escalation, a pattern that occurred in 59% of patients including 11 of 16 
(69%) with jaundice and 2 of 6 (33%) anicteric cases. This finding suggests that the liver 
injury is partially dose-related and that these thiopurines have a degree of intrinsic 
hepatotoxicity at higher doses. The occurrence of sinusoidal obstruction syndrome and 
nodular regeneration with the thiopurines further supports their intrinsic hepatotoxicity, at 
least at higher doses or with longer courses of therapy. Previous experience has shown that 
elevated liver enzymes during thiopurine therapy can often be managed by reducing the dose 
with or without a transient period of withdrawal (19, 31–33). On the other hand, some 
degree of dose-relatedness has been shown for drugs with well defined idiosyncratic liver 
injury, including diclofenac, amoxicillin-clavulanic acid, flucloxacillin and bosentan (34–
36). Indeed, the majority of drugs that are believed to be hepatotoxic are given in doses of 
more than 50 mg daily, suggesting a threshold dose for risk of hepatic injury (36–38). 
Importantly, the finding of a relationship between dose escalation of Aza and MP and the 
risk of liver injury points to the need of informing patients about risk of liver injury and 
monitoring liver tests after increasing the dose. Thus, Aza and 6-MP should be added to a 
growing list of agents that may have both idiosyncratic and intrinsic hepatotoxic potential.
Another striking feature of the cholestatic hepatitis was the somewhat distinctive pattern of 
serum enzyme elevations. Thus, despite the disease being cholestatic (verified by liver 
biopsy), serum Alk P levels were generally low and were normal in many patients at the 
onset of jaundice. A similar pattern of liver enzyme elevations is typical of anabolic steroid 
jaundice (29). However, the clinical course and liver histology of Aza and 6-MP induced 
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liver injury was distinctly different from that of anabolic steroid injury which typically 
causes a prolonged jaundice with severe pruritus and canalicular, bland cholestasis on liver 
biopsy. The reasons for the minimal Alk P elevations accompanying the cholestatic hepatitis 
of Aza and 6-MP injury are not clear, but may reflect the activity of these agents in treating 
liver injury. Both agents are used for immune-mediated forms of hepatitis, and therefore 
might mitigate immune-mediated injury due to the compounds themselves. Another 
possibility, is that the relatively low Alk P levels reflect the effects of concurrent use of 
corticosteroids (common in the population who receive Aza and 6-MP) or to the underlying 
diseases themselves. Regardless, this pattern may be helpful in identifying Aza or 6-MP as a 
cause of liver injury in patients on multiple, potentially hepatotoxic agents or patients with 
other potential causes of liver injury.
The strength of the current study is the prospective collection of data, well characterized 
patients and good follow-up. The limitations include the lack of patients with nodular 
regenerative hyperplasia (NRH) related to these drugs due to the entry criteria which are 
based on liver enzyme elevations. Another limitation as in most other studies on drug-
induced liver injury was that the incidence of liver injury among patients taking these drugs 
could not be estimated. Furthermore, TPMT genotyping was not a part of the study design. 
Some of these such as NRH related to thiopurines and the TPMT genotyping in this context 
have been covered in recent review (39).
Finally, there is a likelihood of cross-sensitivity to cholestatic liver injury due to these two 
purine analogues. Apart from a recurrence of liver injury in a patient with a prevous bout of 
azathioprine induced liver injury, another patient developed prominent hepatotoxicity from 
6-MP after an episode of jaundice while taking Aza. Similar cases have been documented in 
the literature, largely in instances of clinically apparent, icteric liver injury due to these 
agents.
In conclusion, liver injury from Aza and 6-MP most often occurs within 3 months of 
exposure or dose escalation, often in women and usually presenting with non-specific 
symptoms followed by jaundice. Generally two patterns of injury can be seen; (1) a 
transient, mildly symptomatic elevation in serum aminotransferase levels and (2) a 
cholestatic hepatitis with modest elevations in both ALT and Alk P and moderate-to-severe 
jaundice. While the injury can be severe, the prognosis is generally favorable except in 
patients with pre-existing liver disease. Close monitoring of liver tests may be appropriate 
after dose escalation of Aza or 6-MP and the need for treatment in patients with pre-existing 
cirrhosis should be considered carefully before initating therapy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Financial Support: This study was supported by the National Institute of Diabetes and Digestive and Kidney 
Diseases (NIDDK) under the following cooperative agreements: 1UO1DK065201, 1UO1DK065193, 
1UO1DKO65184, 1UO1DK065211, 1UO1DK065238, and 1UO1DK06F5176. This research was supported in part 
by the Intramural Research Programs of the National Cancer Institute and NIDDK, NIH.
Björnsson et al. Page 8
J Clin Gastroenterol. Author manuscript; available in PMC 2017 July 11.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
References
1. McIlvanie SK, MacCarthy JD. Hepatitis in association with prolonged 6-mercaptopurine therapy. 
Blood. 1959; 14:80–90. [PubMed: 13607581] 
2. Clark PA, Hsia YE, Huntsman RG. Toxic complications of treatment with 6-mercaptopurine: two 
cases with hepatic necrosis and intestinal ulceration. Br Med J. 1960; 1:393–5. [PubMed: 
13810473] 
3. Einhorn M, Davidsohn I. Hepatotoxicity of mercaptopurine. JAMA. 1964; 188:802–6. [PubMed: 
14132534] 
4. Krawitt EL, Stein JH, Kirkendall WM, et al. Mercaptopurine hepatotoxicity in a patient with chronic 
active hepatitis. Arch Intern Med. 1967; 120:729–34. [PubMed: 4168362] 
5. Shorey J, Schenker S, Suki WN, et al. Hepatotoxicity of mercaptopurine. Arch Intern Med. 1968; 
122:54–8. [PubMed: 5659378] 
6. Lascari AD, Givier RL, Soper RT, et al. Portal hypertension in a case of acute leukemia treated with 
antimetabolites for 10 years. N Engl J Med. 1968; 279:303–6. [PubMed: 5301748] 
7. Sparberg M, Simon N, Del Greco F. Intrahepatic cholestasis due to azathioprine. Gastroenterology. 
1969; 57:439–41. [PubMed: 4951148] 
8. http://livertox.nlm.nih.gov/Azathioprine.htm
9. Lemarchand P, Desrumeaux B, Bercoff E, et al. Cholestasis and sinusoidal dilatation following 
treatment with azathioprine. Gastroenterol Clin Biol. 1986; 10:853–4.
10. Small P, Lichter M. Probable azathioprine hepatotoxicity: a case report. Ann Allergy. 1989; 
62:518–20. [PubMed: 2735558] 
12. Ramalho HJ, Terra EG, Cartapatti E, et al. Hepatotoxicity of azathioprine in renal transplant 
recipients. Transplant Proc. 1989; 21(1 Pt 2):1716–7. [PubMed: 2652562] 
13. Sterneck M, Wiesner R, Ascher N, et al. Azathioprine hepatotoxicity after liver transplantation. 
Hepatology. 1991; 14:806–10. [PubMed: 1937385] 
14. Hunt CM. Mitochondrial and immunoallergic injury increase risk of positive drug rechallenge after 
drug-induced liver injury: a systematic review. Hepatology. 2010; 52:2216–22. [PubMed: 
21105110] 
15. Andrade RJ, Lucena MI, Fernández MC, et al. Drug-induced liver injury: an analysis of 461 
incidences submitted to the Spanish registry over a 10-year period. Spanish Group for the Study of 
Drug-Induced Liver Disease. Gastroenterology. 2005; 129:512–21. [PubMed: 16083708] 
16. Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a 
prospective study of drug-induced liver injury in the United States. Drug Induced Liver Injury 
Network (DILIN). Gastroenterology. 2008; 135:1924–34. {Update to 2015 paper}. [PubMed: 
18955056] 
17. Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. 
Hepatology. 2005; 42:481–489. [PubMed: 16025496] 
18. Björnsson ES, Bergmann OM, Björnsson HK, et al. Incidence, Presentation and Outcomes in 
Patients with Drug-Induced Liver Injury in the General Population of Iceland. Gastroenterology. 
2013; 144:1419–25. [PubMed: 23419359] 
19. Gearry RB, Barclay ML, Burt MJ, et al. Thiopurine drug adverse effects in a population of New 
Zealand patients with inflammatory bowel disease. Pharmacoepidemiol Drug Saf. 2004; 13(8):
563–7. [PubMed: 15317038] 
20. Bastida G1, Nos P, Aguas M, et al. Incidence, risk factors and clinical course of thiopurine-induced 
liver injury in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2005; 22(9):
775–82. [PubMed: 16225485] 
21. Gisbert JP, Luna M, González-Lama Y, et al. Liver injury in inflammatory bowel disease: long-
term follow-up study of 786 patients. Inflamm Bowel Dis. 2007; 13(9):1106–14. [PubMed: 
17455203] 
22. Shaye OA, Yadegari M, Abreu MT, et al. Hepatotoxicity of 6-mercaptopurine (6-MP) and 
Azathioprine (AZA) in adult IBD patients. Am J Gastroenterol. 2007; 102(11):2488–94. [PubMed: 
17764490] 
Björnsson et al. Page 9
J Clin Gastroenterol. Author manuscript; available in PMC 2017 July 11.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
23. Marubbio AT, Danielson B. Hepatic veno-occlusive disease in a renal transplant patient receiving 
azathioprine. Gastroenterology. 1975; 69:739–43. [PubMed: 1098955] 
24. Fonseca V, Havard CW. Portal hypertension secondary to azathioprine in myasthenia gravis. 
Postgrad Med J. 1988; 64:950–2. [PubMed: 3256814] 
25. Buffet C, Cantarovitch M, Pelletier G, et al. Three cases of nodular regenerative hyperplasia of the 
liver following renal transplantation. Nephrol Dial Transplant. 1988; 3:327–30. [PubMed: 
3140108] 
26. Fontana RJ, Watkins PB, Bonkovsky Hl, et al. Drug-induced Liver Injury Network (DILIN) 
prospective study: rationale, design, and conduct. Drug Saf. 2009; 32:55–68. [PubMed: 19132805] 
27. Rockey DC, Seeff LB, Rochon J, et al. Causality assessment in drug-induced liver injury using a 
structured expert opinion process: comparions to the Roussel-Uclaf causality asessment method. 
Hepatology. 2010; 51:2117–2126. [PubMed: 20512999] 
28. Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based 
on the conclusions of international consensus meetings: application to drug-induced liver injuries. 
J Clin Epidemiol. 1993; 46:1323–30. [PubMed: 8229110] 
29. Zimmerman, HJ. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. 
2. Lippincott Williams & Wilkins; Philadelphia: 1999. p. 433
30. Seksik P, Mary JY, Beaugerie L, et al. Incidence of nodular regenerative hyperplasia in 
inflammatory bowel disease patients treated with azathioprine. Inflamm Bowel Dis. 2011; 17:565–
72. [PubMed: 20848502] 
31. George J1, Present DH, Pou R, Bodian C, Rubin PH. The long-term outcome of ulcerative colitis 
treated with 6-mercaptopurine. Am J Gastroenterol. 1996; 91:1711–4. [PubMed: 8792685] 
32. Markowitz J, Grancher K, Kohn N, Daum F, et al. A multicenter trial of 6-mercaptopurine and 
prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology. 2000; 119:895–
902. [PubMed: 11040176] 
33. Nygaard U, Toft N, Schmiegelow K. Methylated metabolites of 6-mercaptopurine are associated 
with hepatotoxicity. Clin Pharmacol Ther. 2004; 75:274–81. [PubMed: 15060506] 
34. de Abajo FJ, Montero D, Madurga M, et al. Acute and clinically relevant drug-induced liver injury: 
a population based case-control study. Brit J Clin Pharmacol. 2004; 58:71–80. [PubMed: 
15206996] 
35. Kenyon KW, Nappi JM. Bosentan for the treatment of pulmonary arterial hypertension. Ann 
Pharmacother. 2003; 37:1055–62. [PubMed: 12841819] 
36. Lammert C, Einarsson S, Saha C, et al. Relationship between daily dose of oral medications and 
idiosyncratic drug-induced liver injury: search for signals. Hepatology. 2008; 47:2003–9. 
[PubMed: 18454504] 
37. Russo MW, Galanko JA, Shrestha R, et al. Liver transplantation for acute liver failure from drug 
induced liver injury in the United States. Liver Transpl. 2004; 10:1018–23. [PubMed: 15390328] 
38. Lucena MI, Andrade RJ, Kaplowitz N, et al. Phenotypic characterization of idiosyncratic drug-
induced liver injury: the influence of age and sex. Hepatology. 2009; 49:2001–9. [PubMed: 
19475693] 
39. Gisbert JP, Gonzalez-Lama Y, Mate J. Thiopurine-induced liver injury in patients with 
inflammatory bowel disease: a systematic review. Am J Gastroenterol. 2007; 102:1518–27. 
[PubMed: 17391318] 
Björnsson et al. Page 10
J Clin Gastroenterol. Author manuscript; available in PMC 2017 July 11.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Selection and bases for exclusion of cases from the DILIN cohort.
Björnsson et al. Page 11
J Clin Gastroenterol. Author manuscript; available in PMC 2017 July 11.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. 
Latency to onset of laboratory abnormalities in months from start of therapy (left) and from 
the time of the last dose escalation (right) for 12 cases of azathioprine (blue circles) and 10 
cases of 6-mercaptopurine hepatotoxicity (red circles). Calculation of latency from first 
starting the thiopurines yielded a wide range of latencies whereas calculation from the time 
of the last dose increase yielded latencies that were largely within 3 months.
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Figure 3. 
Use of the initial ALT and alkaline phosphatase levels and four quadrants to characterize the 
pattern of liver injury as suggested by Zimmerman (29). The plotting of 12 cases of 
azathioprine (blue circles) and 10 cases of 6-mercaptopurine liver injury (red circles) for 
both icteric (closed circles) and anicteric cases (open circles) shows a similar pattern for the 
two drugs but a different pattern for anicteric cases which were typically hepatocellular 
compared to the icteric cases which were typically cholestatic but with modest alkaline 
phosphatase elevations which is typical of canalicular as opposed to hepatocanalicular 
cholestasis.
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Figure 4. 
Liver biopsy histology from [Case #20 described in Supplementary material] shows 
cholestatic hepatitis with nodular regenerative hyperplasia due to 6-mercaptopurine liver 
injury. a. Portal inflammation consists mainly of foamy macrophages with scattered 
neutrophils (H&E, 400x). b: Bile stasis (arrowheads) is evident in zone 3 (H&E, 600x). c: A 
reticulin stain shows small nodular areas of hepatocyte plate expansion bounded by 
narrowed, atrophic hepatocyte plates (200x).
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Table 1
Clinical Features
Feature Azathioprine (n=12) Mercaptopurine (n=10) P value
Female Sex 9 (75%) 6 (60%) 0.65
Age (years) * 57 (41–67) 49 (11–63) 0.17
Race (no)
White, non-Hispanic 10 (83%) 9 (90%)
White, Hispanic 0 1 (10%) 0.48
African American 2 (17%) 0
Indication
IBD 5 7
Pulmonary 3 0 0.18
Other Autoimmune 4 2
Leukemia 0 1
Causality
Definite 1 1
Very Likely 7 5 0.82
Probable 4 4
RUCAM * 7.0 (4–10) 6.0 (5–9) 0.42
Time to Onset (days) * 41 (3–455) 96 (53–2584) 0.06
Time from Last Dose Increase to Onset (days) * 31 (3–116) 64 (23–254) 0.07
Initial daily dose [n=12] [n=9]
in mg * 75 (25–150) 100 (50–200) 0.36
in mg/kg* 0.9 (0.3–2.1) 1.0 (0.5–1.8) 0.79
Final daily dose [n=11] [n=9]
in mg * 138 (50–450) 158 (100–300) 0.14
in mg/kg* 1.8 (0.5–4.9) 1.5 (1.0–2.7) 0.91
Symptoms:
Any 12 (100%) 9 (90%) 0.46
Fatigue 7 4 0.67
Nausea 8 6 1.00
Abdominal Pain 7 4 0.67
Jaundice 7 8 0.38
Itching 3 3 1.00
Fever 3 3 1.00
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Feature Azathioprine (n=12) Mercaptopurine (n=10) P value
Rash 3 2 1.00
*
Median (and range)
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Table 2
Laboratory Features
Feature Azathioprine (n=12) Mercaptopurine (n=10) P value
Initial ALT (U/L) * 254 (116–625) 121 (64–539) 0.03
Initial AST (U/L) * 197 (70–603) 100 (47–515) 0.04
Initial Alk P (U/L) * 190 (77–412) 143 (35–187) 0.08
Initial R ratio * 4.0 (1.9–13.1) 2.5 (1.1–22.4) 0.32
Initial Bilirubin (mg/dL) * 6.7 (0.6–31.8) 10.6 (0.7–21.9) 0.51
Peak Bilirubin (mg/dL) * 7.7 (0.6–39.4) 20.0 (1.3–37.6) 0.15
Peak INR * 1.1 (0.9–7.0) 1.5 (0.9–2.4) 0.08
Initial R ratio
Cholestatic (<2) 1 5
Mixed (2–5) 7 2 0.19
Hepatocellular (>5) 4 3
Severity Score (no)
1 4 2
2–3 6 3 0.16
4–5 2 5
Time to fall from peak bilirubin to less than 2.5 mg/dL * (days) [n=9] [n=8]
42 35 0.29
Chronic elevations (≥1 yr) [n=10] [n=9]
ALT 1** 0
Alk P 0 1 0.47
Bilirubin 0 0
*
Median (and range).
**
This patient had chronic hepatitis C and ALT elevations before starting azathioprine.
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